AbCellera Biologics (ABCL) Short Interest Ratio & Short Volume $2.85 +0.14 (+5.17%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AbCellera Biologics Short Interest DataAbCellera Biologics (ABCL) has a short interest of 16.25 million shares, representing 7.33% of the float (the number of shares available for trading by the public). This marks a 2.01% increase in short interest from the previous month. The short interest ratio (days to cover) is 7.4, indicating that it would take 7.4 days of the average trading volume of 1.77 million shares to cover all short positions.Current Short Interest16,250,000 sharesPrevious Short Interest15,930,000 sharesChange Vs. Previous Month+2.01%Dollar Volume Sold Short$48.91 millionShort Interest Ratio7.4 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares295,366,000 sharesFloat Size221,750,000 sharesShort Percent of Float7.33%Today's Trading Volume2,074,423 sharesAverage Trading Volume1,770,256 sharesToday's Volume Vs. Average117% Short Selling AbCellera Biologics? Sign up to receive the latest short interest report for AbCellera Biologics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartABCL Short Interest Over TimeABCL Days to Cover Over TimeABCL Percentage of Float Shorted Over Time Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. AbCellera Biologics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/202416,250,000 shares $48.91 million +2.0%7.3%7.4 $3.01 11/15/202415,930,000 shares $42.21 million -4.3%7.2%7.3 $2.65 10/31/202416,640,000 shares $45.43 million -4.1%8.0%8.1 $2.73 10/15/202417,350,000 shares $44.42 million +1.7%8.4%9.4 $2.56 9/30/202417,060,000 shares $44.36 million +1.3%8.3%9.8 $2.60 9/15/202416,840,000 shares $46.31 million -4.1%8.2%9 $2.75 Get the Latest News and Ratings for ABCL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter. 8/31/202417,550,000 shares $44.93 million -3.4%8.5%9.2 $2.56 8/15/202418,170,000 shares $47.61 million +4.3%8.8%10.7 $2.62 7/31/202417,420,000 shares $56.79 million -2.0%8.4%10.6 $3.26 7/15/202417,770,000 shares $56.86 million -5.4%8.6%10.7 $3.20 6/30/202418,780,000 shares $55.59 million -4.8%9.1%11.5 $2.96 6/15/202419,720,000 shares $63.70 million +7.1%9.6%13.1 $3.23 5/31/202418,420,000 shares $72.21 million -6.7%8.9%14.6 $3.92 5/15/202419,750,000 shares $73.08 million -15.2%9.6%14.6 $3.70 4/30/202423,290,000 shares $88.04 million +0.9%11.3%16.8 $3.78 4/15/202423,090,000 shares $96.52 million -2.1%11.3%17.4 $4.18 3/31/202423,590,000 shares $106.86 million +2.4%11.5%16.7 $4.53 3/15/202423,040,000 shares $108.52 million +1.1%11.2%16 $4.71 2/29/202422,780,000 shares $115.04 million -0.1%11.1%14.8 $5.05 2/15/202422,810,000 shares $120.44 million -6.9%11.4%14.6 $5.28 1/31/202424,490,000 shares $125.14 million -2.3%12.3%16.8 $5.11 1/15/202425,070,000 shares $135.13 million -2.0%12.6%16.6 $5.39 12/31/202325,580,000 shares $146.06 million -3.2%12.9%16.7 $5.71 12/15/202326,420,000 shares $143.46 million -2.2%13.3%16.9 $5.43 11/30/202327,000,000 shares $127.17 million -1.7%13.6%16.8 $4.71 11/15/202327,470,000 shares $124.44 million -1.2%13.9%17.8 $4.53 10/31/202327,810,000 shares $114.30 million +5.5%14.0%17 $4.11 10/15/202326,370,000 shares $112.34 million +2.5%13.4%15 $4.26 9/30/202325,720,000 shares $118.31 million +1.7%13.0%13.6 $4.60 9/15/202325,290,000 shares $135.05 million -4.2%12.8%12.4 $5.34 8/31/202326,390,000 shares $143.83 million -4.2%13.4%10 $5.45 8/15/202327,550,000 shares $152.08 million +4.3%14.0%9.2 $5.52 7/31/202326,410,000 shares $204.15 million +4.9%13.4%8.3 $7.73 7/15/202325,170,000 shares $180.22 million -0.3%12.8%8.1 $7.16 6/30/202325,240,000 shares $163.05 million -12.9%12.8%8.7 $6.46 6/15/202328,960,000 shares $216.62 million +11.5%14.7%10.3 $7.48 5/31/202325,970,000 shares $181.01 million -2.4%13.2%12 $6.97 5/15/202326,620,000 shares $159.19 million +8.5%13.5%13.5 $5.98 4/30/202324,530,000 shares $166.31 million +4.0%12.5%14.1 $6.78 4/15/202323,590,000 shares $174.09 million +0.1%12.0%14.9 $7.38Did You See Trump’s Bombshell Exec. Order 001? (Ad)Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. 3/31/202323,560,000 shares $177.64 million +2.2%12.0%14.4 $7.54 3/15/202323,050,000 shares $171.26 million +4.0%11.8%13.6 $7.43 2/28/202322,170,000 shares $186.23 million +9.0%11.3%12 $8.40 2/15/202320,340,000 shares $202.99 million +6.3%10.5%10.9 $9.98 1/31/202319,130,000 shares $201.44 million -2.8%9.9%10.1 $10.53 1/15/202319,680,000 shares $204.28 million +29.9%10.1%9.8 $10.38 12/30/202215,150,000 shares $153.47 million -1.3%7.8%7.6 $10.13 12/15/202215,350,000 shares $159.64 million -7.0%7.9%7.6 $10.40 11/30/202216,510,000 shares $212.48 million -7.3%8.5%8.7 $12.87 11/15/202217,800,000 shares $257.92 million -2.4%9.2%10.3 $14.49 10/31/202218,230,000 shares $215.66 million -6.7%9.4%10 $11.83 10/15/202219,530,000 shares $201.94 million +0.6%10.1%11.1 $10.34 9/30/202219,410,000 shares $191.96 million -10.2%10.1%10.6 $9.89 9/15/202221,620,000 shares $235.23 million +7.8%11.6%9.6 $10.88 8/31/202220,050,000 shares $214.13 million +3.7%10.8%7.7 $10.68 8/15/202219,340,000 shares $261.86 million +1.0%10.4%7.2 $13.54 7/31/202219,140,000 shares $192.17 million -0.5%10.3%7 $10.04 7/15/202219,230,000 shares $202.68 million +0.2%10.3%7.3 $10.54 6/30/202219,200,000 shares $204.48 million +56.5%10.3%7.5 $10.65 6/15/202212,270,000 shares $113.74 million +13.9%6.6%4.9 $9.27 5/31/202210,770,000 shares $82.07 million -9.9%5.8%5.8 $7.62 5/15/202211,950,000 shares $86.40 million +2.0%6.4%6.5 $7.23 4/30/202211,720,000 shares $89.89 million -9.1%6.2%6.8 $7.67 4/15/202212,890,000 shares $115.88 million +7.2%6.9%6.8 $8.99 3/31/202212,030,000 shares $117.29 million +5.5%6.4%5.8 $9.75 3/15/202211,400,000 shares $88.58 million +8.5%6.1%5.6 $7.77 2/28/202210,510,000 shares $91.54 million -11.5%5.6%4.8 $8.71 2/15/202211,880,000 shares $118.56 million -2.5%6.4%5.5 $9.98 1/31/202212,190,000 shares $109.59 million -3.6%7.2%5.8 $8.99 1/15/202212,650,000 shares $127.13 million +19.7%7.6%6.4 $10.05 12/31/202110,570,000 shares $151.15 million +9.8%6.3%5.8 $14.30 12/15/20219,630,000 shares $125.09 million -14.2%5.8%4.9 $12.99 11/30/202111,220,000 shares $167.85 million +7.3%6.7%4.8 $14.96 11/15/202110,460,000 shares $171.44 million -1.4%6.3%4.5 $16.39 10/29/202110,610,000 shares $166.68 million +5.2%6.5%4.3 $15.71 10/15/202110,090,000 shares $156.70 million +24.3%6.2%4.2 $15.53 9/30/20218,120,000 shares $162.72 million +3.3%5.0%3.3 $20.04 9/15/20217,860,000 shares $147.85 million +1.6%4.8%3.3 $18.81 8/31/20217,740,000 shares $129.88 million -26.2%4.8%3.7 $16.78 8/13/202110,490,000 shares $187.67 million +22.7%6.6%5.1 $17.89 7/30/20218,550,000 shares $129.70 million +0.2%5.5%4.9 $15.17 7/15/20218,530,000 shares $141.00 million +1.8%5.3%5.3 $16.53 6/30/20218,380,000 shares $184.36 million +17.7%5.2%5.3 $22.00 6/15/20217,120,000 shares $167.53 million -6.1%4.5%4.7 $23.53 5/28/20217,580,000 shares $203.37 million -10.1%5.1%6.4 $26.83 5/14/20218,430,000 shares $287.80 million +31.9%5.6%7.9 $34.14 4/30/20216,390,000 shares $183.90 million +8.3%4.3%5.9 $28.78 4/15/20215,900,000 shares $166.68 million -4.8%3.9%5.6 $28.25 3/31/20216,200,000 shares $165.42 million +53.9%4.1%5.7 $26.68 3/15/20214,030,000 shares $147.26 million +79.9%2.7%4.4 $36.54Did You See Trump’s Bombshell Exec. Order 001? (Ad)Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. 2/26/20212,240,000 shares $87.49 million -23.0%1.5%1.9 $39.06 2/12/20212,910,000 shares $133.86 million -37.3%2.0%2.4 $46.00 1/29/20214,640,000 shares $238.96 million -6.1%3.1%3.6 $51.50 1/15/20214,940,000 shares $230.40 million No Change3.2%3.4 $46.64 ABCL Short Interest - Frequently Asked Questions What is AbCellera Biologics' current short interest? Short interest is the volume of AbCellera Biologics shares that have been sold short but have not yet been closed out or covered. As of November 30th, investors have sold 16,250,000 shares of ABCL short. 7.33% of AbCellera Biologics' shares are currently sold short. Learn More on AbCellera Biologics' current short interest. What is a good short interest ratio for AbCellera Biologics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ABCL shares currently have a short interest ratio of 7.0. Learn More on AbCellera Biologics's short interest ratio. Which institutional investors are shorting AbCellera Biologics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of AbCellera Biologics: National Bank of Canada FI. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for AbCellera Biologics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.33% of AbCellera Biologics' floating shares are currently sold short. Is AbCellera Biologics' short interest increasing or decreasing? AbCellera Biologics saw a increase in short interest in the month of November. As of November 30th, there was short interest totaling 16,250,000 shares, an increase of 2.0% from the previous total of 15,930,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is AbCellera Biologics' float size? AbCellera Biologics currently has issued a total of 295,366,000 shares. Some of AbCellera Biologics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. AbCellera Biologics currently has a public float of 221,750,000 shares. How does AbCellera Biologics' short interest compare to its competitors? 7.33% of AbCellera Biologics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to AbCellera Biologics: MoonLake Immunotherapeutics (15.15%), Edgewise Therapeutics, Inc. (9.20%), Janux Therapeutics, Inc. (9.53%), Xenon Pharmaceuticals Inc. (3.78%), Amicus Therapeutics, Inc. (6.97%), Merus (12.74%), ACADIA Pharmaceuticals Inc. (5.96%), MorphoSys AG (0.09%), Zai Lab Limited (4.76%), Vera Therapeutics, Inc. (13.29%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short AbCellera Biologics stock? Short selling ABCL is an investing strategy that aims to generate trading profit from AbCellera Biologics as its price is falling. ABCL shares are trading up $0.14 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against AbCellera Biologics? A short squeeze for AbCellera Biologics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ABCL, which in turn drives the price of the stock up even further. How often is AbCellera Biologics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ABCL, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies MoonLake Immunotherapeutics Short Squeeze Edgewise Therapeutics Short Squeeze Janux Therapeutics Short Squeeze Xenon Pharmaceuticals Short Squeeze Amicus Therapeutics Short Squeeze Merus Short Squeeze ACADIA Pharmaceuticals Short Squeeze MorphoSys Short Squeeze Zai Lab Short Squeeze Vera Therapeutics Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ABCL) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABCL Stock Alerts